Table 3.
Baseline to end of RT | Baseline to 3 months post-RT | |||||
---|---|---|---|---|---|---|
All (n = 447) |
WPRT (n = 386) |
PORT (n = 61) |
All (n = 371) |
WPRT (n = 320) |
PORT (n = 51) |
|
Minimum | −608.07 | −608.07 | −293.95 | −478.39 | −478.39 | −315.85 |
5th percentile | −270.00 | −288.18 | −178.67 | −228.00 | −240.50 | −182.00 |
Q1 | −109.00 | −110.00 | −57.64 | −99.00 | −100.50 | −86.46 |
Median | −30.00 | −35.29 | −11.00 | −34.00 | −31.35 | −41.00 |
Q3 | 38.62 | 40.00 | 29.00 | 32.00 | 41.61 | 15.00 |
95th percentile | 162.00 | 172.00 | 125.00 | 160.00 | 169.00 | 65.00 |
Maximum | 593.66 | 593.66 | 158.50 | 691.00 | 691.00 | 86.46 |
P-valuea | < .001 | < .001 | .128 | < .001 | < .001 | < .001 |
P-valueb | .216 | .277 |
PORT, prostate-only radiation therapy; Q1, first quartile; Q3, third quartile; RT, radiation therapy; WPRT, whole pelvis radiation therapy.
P-value from Wilcoxon signed-rank test comparing to 0.
P -value comparing WPRT vs. PORT from Wilcoxon test.